PIONEER IN ALZHEIMERS RESEARCH NOMINATED AS AN INTERNATIONAL SCIENTIST OF THE YEAR

The International Biographical Centre of Cambridge, England, confirmed the nomination of Dr. William K. Summers as an International Scientist of the Year for 2002.

The International Biographical Centre of Cambridge, England, confirmed the nomination of Dr. William K. Summers as an International Scientist of the Year for 2002. This award is made available to only a distinguished few individuals whose achievements and leadership stand out in the international scientific community.

Dr. Summers is one of the pioneers in Alzheimers research. As a physician-researcher, he has researched Alzheimers disease since 1977, and has worked with memory-impaired patients for over twenty years. His research led to the FDA approval of Tacrine (Cognex) as the first safe and effective treatment of Alzheimers disease. He has developed an all-inclusive approach to the diagnosis and care of the memory-impaired patient, combining currently available treatments and medications with neuroceutical supplements. Memory Support" (patent-pending), developed by Dr. Summers, is a uniquely formulated neuroceutical supplement designed to slow degenerative aging effects on the brain, improve memory and generally increase energy. Memory Support" is currently being produced and is sold through the Alzheimers Corporation website and in Alzheimers Clinics.

Founded in 1999, Alzheimers Corporation is dedicated to the diagnosis and care of the memory-impaired elderly within the community. The mission of Alzheimers Corporation is to improve quality of life for both patient and caregiver through proper and rapid diagnosis, aggressive treatment with currently available drugs and neuroceuticals, while providing substantial savings to patients and families who are facing long-term care costs. Currently, Dr. Summers focus has been directed toward raising the capital necessary for production of the second neuroceutical.

More information about Alzheimers Corporation and services to patients and caregivers may be found on its website at www.AlzheimersCorp.com.